Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 4/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 6/20 | 0.43 |
| ▸ | ACE | P12821 | 6/20 | 0.43 |
| ▸ | TPH1 | P17752 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283122 | 0.85 | ENPEP (0.49) | ENPEPPPARAMMEACEANPEP | |
| SCHEMBL15134788 | 0.85 | ENPEP (0.49) | ENPEPMMEACEANPEP | |
| SCHEMBL15147804 | 0.85 | ENPEP (0.49) | ENPEPPPARAMMEACEANPEP | |
| SCHEMBL12873867 | 0.85 | ENPEP (0.49) | ENPEPMMEACEANPEP | |
| SCHEMBL12879843 | 0.85 | ENPEP (0.49) | ENPEPMMEACEANPEP | |
| SCHEMBL10063295 | 0.85 | SLC7A5 (0.59) | ENPEPMMEACE | |
| SCHEMBL15147781 | 0.85 | ENPEP (0.49) | ENPEPPPARAMMEACEANPEP | |
| SCHEMBL16410936 | 0.85 | ALPI (0.56) | ENPEPMMEACEANPEP | |
| SCHEMBL10063806 | 0.85 | ALPI (0.56) | ENPEPMMEACEANPEP | |
| SCHEMBL22199422 | 0.85 | ALPI (0.56) | ENPEPMMEACEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980833-B2 | Tubulysine derivatives | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| EP-2532673-A2 | Tubulysine derivatives | R & D Biopharmaceuticals Gmbh (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2008138561-A1 | TUBULYSINE DERIVATIVES | R & D BIOPHARMACEUTICALS GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | GLS, TPX2, HKDC1 | ENPEP 313/4885TRPA1 4002/4885PPARD 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.